Histogenics Corporation (HSGX) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research lowered shares of Histogenics Corporation (NASDAQ:HSGX) from a buy rating to a hold rating in a research report released on Monday morning.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

Several other analysts have also recently weighed in on the company. ValuEngine raised Histogenics Corporation from a strong sell rating to a sell rating in a report on Friday, June 23rd. HC Wainwright set a $4.00 price objective on Histogenics Corporation and gave the stock a buy rating in a report on Friday, August 11th. Finally, Canaccord Genuity reissued a buy rating and set a $4.00 price objective on shares of Histogenics Corporation in a report on Friday, August 11th.

Histogenics Corporation (NASDAQ HSGX) traded up 0.92% during trading on Monday, hitting $2.20. 38,269 shares of the stock traded hands. Histogenics Corporation has a 52 week low of $1.45 and a 52 week high of $3.00. The firm’s 50-day moving average is $2.04 and its 200 day moving average is $1.82. The stock’s market cap is $49.48 million.

Histogenics Corporation (NASDAQ:HSGX) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.06. During the same period in the prior year, the firm earned ($0.61) EPS. Equities research analysts forecast that Histogenics Corporation will post ($1.09) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Histogenics Corporation (HSGX) Downgraded by Zacks Investment Research to Hold” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/10/20/histogenics-corporation-hsgx-downgraded-by-zacks-investment-research-to-hold.html.

Histogenics Corporation Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get a free copy of the Zacks research report on Histogenics Corporation (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply